Aringer M - Search Results

1

Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease.

Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold AM, Kuwana M, Merkel PA, Stock C, Sambevski S, Denton CP; SENSCIS Trial Investigators. Allanore Y, et al. Among authors: aringer m. Rheumatology (Oxford). 2024 Mar 1;63(3):639-647. doi: 10.1093/rheumatology/kead280. Rheumatology (Oxford). 2024. PMID: 37294870 Free PMC article. Clinical Trial.

2

Physical exercise is associated with less fatigue, less pain and better sleep in patients with systemic lupus erythematosus.

Wohland H, Aringer M, Leuchten N. Wohland H, et al. Among authors: aringer m. Clin Exp Rheumatol. 2024 Mar;42(3):601-607. doi: 10.55563/clinexprheumatol/az3pkn. Epub 2023 Sep 6. Clin Exp Rheumatol. 2024. PMID: 37706288

3

Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood.

Günther C, Wolf C, Fennen L, Rösing S, Beissert S, Aringer M, Lee-Kirsch MA. Günther C, et al. Among authors: aringer m. Front Immunol. 2023 Sep 21;14:1253279. doi: 10.3389/fimmu.2023.1253279. eCollection 2023. Front Immunol. 2023. PMID: 37809086 Free PMC article.

4

Who will respond to type I interferon receptor blockade in SLE?

Aringer M. Aringer M. Lancet Rheumatol. 2022 Apr;4(4):e234-e236. doi: 10.1016/S2665-9913(21)00370-2. Epub 2022 Feb 3. Lancet Rheumatol. 2022. PMID: 38288920 No abstract available.

5

Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.

Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony SH, Bao M; GiACTA investigators. Stone JH, et al. Among authors: aringer m. Lancet Rheumatol. 2021 May;3(5):e328-e336. doi: 10.1016/S2665-9913(21)00038-2. Epub 2021 Mar 19. Lancet Rheumatol. 2021. PMID: 38279390

6

Classification of systemic lupus erythematosus: From the development of classification criteria to a new taxonomy?

Aringer M, Toro-Domínguez D, Alarcón-Riquelme ME. Aringer M, et al. Best Pract Res Clin Rheumatol. 2024 May 9:101949. doi: 10.1016/j.berh.2024.101949. Online ahead of print. Best Pract Res Clin Rheumatol. 2024. PMID: 38729901 Free article. Review.

7

[Baricitinib for systemic lupus erythematosus].

Aringer M, Nitschmann S. Aringer M, et al. Inn Med (Heidelb). 2023 Aug;64(8):815-818. doi: 10.1007/s00108-023-01547-5. Epub 2023 Jul 11. Inn Med (Heidelb). 2023. PMID: 37432406 German. No abstract available.

8

Updating the core domains set in Systemic Lupus Erythematosus: Work planned by the Systemic Lupus Erythematosus OMERACT working group.

Nielsen W, Strand V, Simon LS, Thumboo J, Mosca M, Aringer M, Morand EF, Bruce I, Touma Z. Nielsen W, et al. Among authors: aringer m. Lupus. 2023 Apr;32(4):586-588. doi: 10.1177/09612033231162769. Epub 2023 Mar 13. Lupus. 2023. PMID: 36912276 No abstract available.

9

SLE criteria are by necessity still based on clinical (and immunological) criteria items.

Aringer M, Mosca M. Aringer M, et al. Expert Rev Clin Immunol. 2024 Mar;20(3):305-311. doi: 10.1080/1744666X.2023.2292188. Epub 2023 Dec 11. Expert Rev Clin Immunol. 2024. PMID: 38073566 Review.

10

[Assessment tools for systemic lupus erythematosus].

Aringer M, Leuchten N. Aringer M, et al. Z Rheumatol. 2023 Jun;82(5):361-367. doi: 10.1007/s00393-023-01359-w. Epub 2023 May 15. Z Rheumatol. 2023. PMID: 37188996 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

302 results

Search Page